Q Therapeutics' ALS candidate gets orphan status from FDA

11/19/2013 | Salt Lake Tribune (Utah), The

The FDA granted orphan-drug status to Q Therapeutics' experimental drug Q-Cells as a treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease. The designation will give the stem cell drug developer several incentives such as tax credits and seven years of market exclusivity.

View Full Article in:

Salt Lake Tribune (Utah), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN